Patent Board Grants Inter Partes Review Of Cancer-Fighting Therapy
(Decision available. Document #16-160606-032Z.)
Respondent Janssen Oncology Inc.’s U.S. patent No. 8,822,438 describes administration of an effective amount of 17α-hydroxylase/C17, 20-lyase (CYP17) — an enzyme involved in testosterone synthesis — inhibitor, such as abiraterone acetate, with a...
To view the full article, register now.